Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DESYNA
- Development stage
- Preclinical
- Lead developer
- Draupnir Bio
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral, Injectable
01
Overview
DESYNA is a therapeutic research program developed by Draupnir Bio in collaboration with Aarhus University, targeting the degradation of extracellular alpha-synuclein (α-syn) aggregates for the treatment of Parkinson's disease. The program utilizes Draupnir Bio's proprietary SORTAC (sortilin-based lysosome targeting chimera) technology, which employs bifunctional molecules to bind toxic α-syn aggregates and direct them to the lysosome for degradation via the sortilin receptor. This approach aims to halt disease progression by preventing the cell-to-cell spread of rogue protein aggregates. The project is exploring both oral small molecule and injectable biologic modalities and is currently in the preclinical stage with support from Innovation Fund Denmark.
- Other names
- Degradation of Extracellular α-SYNuclein AggregatesDESYNA project
02
Targets
SORT1 (Sortilin)SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on DESYNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DESYNA.